Sierra Oncology

Sierra Oncology was a late-stage drug development company based in Vancouver and California focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor for the treatment of myelofibrosis with potential benefit to patients with anaemia. The company was listed on the NASDAQ with the ticker SRRA was a VIPE (Venture Investment in Public Equity). In 2022, following a positive Phase III clinical study in second-line myelofibrosis patients, GSK acquired SRRA for $1.9bn. The following year, momelotinib was approved by the FDA as Ojjaara®, for patients who have myelofibrosis with anemia.